- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01731899
Agomelatine in Depressed Patients With Fibromyalgia
Observational Study Evaluating the Efficacy and Tolerability of Agomelatine in the Treatment of Depressed Patients With Fibromyalgia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
One of the most frequent comorbidities of fibromyalgia is major depression. Agomelatine is a new antidepressant whose mechanims of action include both agonism at melatonin receptores and 5-HT2C blocking properties which, in addition to antidepressant efficacy, has shown sleep-improving properties. As unrefreshed sleep is a common symptom in fibromyalgia we hypothetized that agomelatine treatment of patients with concomitant depression and fibromyalgia could improve both depressive symtomatology and sleep quality. Thus, the objectives of the present study are the following:
- to assess the effectiveness and tolerability of agomelatine on the severity of depressive symptomatology in patients with fibromyalgia and concomitatnt depresssion
- to evaluate the effect of agomelatine treatment on sleep quality in these patients
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Granada, Spain, 18012
- Instituto de Neurociencias
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- adult patients
- diagnosed of fibromyalgia according to the American College of Rheumatology criteria
- diagnosed of major depression according to the DSM-IV criteria with a BDI-II score equal or higher tahn 20
Exclusion Criteria:
- other psychiastric concomitant illness
- pregnancy or lactation
- patients previously treated with agomelatine with little or no effect
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
agomelatine
patients diagnosed of fibromyalgia and concomitant major depression receiving agomelatine for this later disease
|
Agomelatine 25 mg pills.
Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change, from baseline to endpoint, in the Beck's depression inventory score
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change, from baseline to endpoint, in the Pittsburgh Sleep Quality Inventory
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Elena P Calandre, MD, Universidad de Granada
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Nervous System Diseases
- Mood Disorders
- Musculoskeletal Diseases
- Rheumatic Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Depressive Disorder
- Depression
- Fibromyalgia
- Myofascial Pain Syndromes
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Hypnotics and Sedatives
- S 20098
Other Study ID Numbers
- AGO-2010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fibromyalgia
-
University of AberdeenCompletedFibromyalgia | Fibromyalgia, Primary | Fibromyalgia, SecondaryUnited Kingdom
-
Eli Lilly and CompanyCompletedFibromyalgia, Primary | Fibromyalgia, SecondaryMexico
-
Rasmia ElgoharyNot yet recruiting
-
Spaulding Rehabilitation HospitalNot yet recruiting
-
Cairo UniversityNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed
-
University of UtahTerminated
-
State University of New York - Upstate Medical...CompletedFibromyalgia, PrimaryUnited States
-
University of Sao Paulo General HospitalFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Tel-Aviv Sourasky Medical CenterCompletedFibromyalgia (FM)Israel
Clinical Trials on agomelatine
-
First Affiliated Hospital, Sun Yat-Sen UniversityNot yet recruitingDepression | Acute Ischemic Stroke
-
National Taiwan University HospitalWithdrawnDepressive Disorder, MajorTaiwan
-
Central Institute of Mental Health, MannheimServierCompletedSchizophrenia | Schizoaffective Disorder | Delusional DisorderGermany
-
Novartis PharmaceuticalsServierCompleted
-
NovartisCompletedMajor Depressive DisorderUnited States, Puerto Rico
-
NovartisCompletedMajor Depressive DisorderUnited States
-
NovartisCompletedMajor Depressive Disorder (MDD)United States
-
Novartis PharmaceuticalsCompletedMajor Depressive DisorderUnited States, Puerto Rico
-
Novartis PharmaceuticalsCompletedMajor Depressive DisorderUnited States, Puerto Rico
-
Kahramanmaras Sutcu Imam UniversityCompleted